Arcus Biosciences (NYSE:RCUS) President Juan Jaen Sells 82,997 Shares of Stock

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 82,997 shares of the company’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $24.71, for a total value of $2,050,855.87. Following the completion of the sale, the president owned 954,063 shares in the company, valued at $23,574,896.73. This trade represents a 8.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Arcus Biosciences Stock Up 1.0%

Shares of NYSE:RCUS opened at $25.50 on Friday. The company’s fifty day moving average is $19.25 and its 200-day moving average is $13.13. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65. Arcus Biosciences, Inc. has a 52 week low of $6.50 and a 52 week high of $26.40. The company has a market capitalization of $2.75 billion, a PE ratio of -7.41 and a beta of 0.75.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.33) by $0.06. The firm had revenue of $26.00 million during the quarter, compared to the consensus estimate of $19.89 million. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The firm’s quarterly revenue was down 45.8% on a year-over-year basis. During the same period last year, the firm posted ($1.00) EPS. Equities research analysts predict that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Arcus Biosciences

Hedge funds have recently added to or reduced their stakes in the company. Amalgamated Bank raised its holdings in shares of Arcus Biosciences by 3.9% in the third quarter. Amalgamated Bank now owns 19,533 shares of the company’s stock valued at $266,000 after purchasing an additional 736 shares during the last quarter. Creative Planning grew its position in Arcus Biosciences by 2.7% in the third quarter. Creative Planning now owns 29,629 shares of the company’s stock valued at $403,000 after purchasing an additional 771 shares in the last quarter. GAMMA Investing LLC increased its stake in Arcus Biosciences by 59.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock valued at $37,000 after buying an additional 1,021 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in Arcus Biosciences by 8.0% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,398 shares of the company’s stock valued at $142,000 after buying an additional 1,294 shares during the last quarter. Finally, Parallel Advisors LLC lifted its position in Arcus Biosciences by 1.6% during the 2nd quarter. Parallel Advisors LLC now owns 88,007 shares of the company’s stock worth $716,000 after buying an additional 1,422 shares in the last quarter. Institutional investors own 92.89% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcus Biosciences in a report on Wednesday, October 8th. Bank of America raised their target price on Arcus Biosciences from $17.00 to $26.00 and gave the company a “neutral” rating in a research note on Friday, November 28th. HC Wainwright upped their price target on shares of Arcus Biosciences from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Citigroup increased their price objective on shares of Arcus Biosciences from $54.00 to $56.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Finally, The Goldman Sachs Group boosted their target price on shares of Arcus Biosciences from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Thursday, October 30th. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.44.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.